Scleroderma Pipeline

DelveInsight’s, “Scleroderma Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Scleroderma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Scleroderma Understanding

Scleroderma Overview

Scleroderma, also known as systemic sclerosis, is a rare chronic autoimmune connective tissue disease characterized by excessive collagen production, fibrosis of the skin and internal organs, vascular abnormalities, and immune system dysfunction. The disease can range from localized skin involvement to severe systemic disease affecting the lungs, heart, kidneys, gastrointestinal tract, and blood vessels. Common symptoms include skin thickening, Raynaud’s phenomenon, joint stiffness, fatigue, and organ dysfunction. Scleroderma occurs more commonly in women and usually develops between 30 and 50 years of age. 
The exact cause of scleroderma remains unknown, but it is believed to result from a combination of genetic susceptibility, immune system abnormalities, vascular injury, and environmental triggers. Researchers suggest that certain genes may increase the risk of developing the disease, while factors such as viral infections, silica exposure, organic solvents, and other environmental agents may contribute to disease onset in susceptible individuals. The immune system becomes abnormally activated and stimulates fibroblasts to produce excessive collagen, leading to tissue fibrosis and organ damage.

The pathophysiology of scleroderma involves three major processes: immune dysregulation, vasculopathy, and fibrosis. Endothelial cell injury and abnormal vascular responses lead to narrowing of small blood vessels and impaired blood flow, which contributes to Raynaud’s phenomenon and tissue ischemia. Immune activation causes the release of cytokines and growth factors that stimulate fibroblasts to overproduce collagen and extracellular matrix proteins. Progressive fibrosis then develops in the skin and internal organs, resulting in thickened skin, pulmonary fibrosis, gastrointestinal dysfunction, renal complications, and cardiac involvement.

Diagnosis of scleroderma is based on clinical evaluation, medical history, physical examination, laboratory testing, and imaging studies. Physicians assess symptoms such as skin thickening, Raynaud’s phenomenon, digital ulcers, and organ involvement. Blood tests commonly detect antinuclear antibodies (ANA) and disease-specific autoantibodies such as anti-centromere and anti-topoisomerase I (Scl-70) antibodies. Additional investigations may include pulmonary function tests, echocardiography, high-resolution CT scans, nailfold capillaroscopy, and skin biopsy to evaluate disease extent and organ complications. Early diagnosis is important to prevent irreversible organ damage.

There is currently no cure for scleroderma, so treatment focuses on symptom management, slowing disease progression, and preventing complications. Immunosuppressive therapies such as mycophenolate mofetil, methotrexate, and cyclophosphamide are often used to reduce immune activity and fibrosis. Vasodilators including calcium channel blockers and endothelin receptor antagonists help improve blood flow and manage Raynaud’s phenomenon or pulmonary hypertension. Additional treatments may address gastrointestinal symptoms, kidney disease, skin involvement, and lung fibrosis. Physical therapy, occupational therapy, and regular monitoring are also important components of long-term disease management.

"Scleroderma Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Scleroderma pipeline landscape is provided which includes the disease overview and Scleroderma treatment guidelines. The assessment part of the report embraces, in depth Scleroderma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Scleroderma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Scleroderma Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Scleroderma R&D. The therapies under development are focused on novel approaches to treat/improve Scleroderma. 

Scleroderma Emerging Drugs Analysis

This segment of the Scleroderma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Scleroderma Emerging Drugs

Belimumab: GSK

Belimumab is a fully human monoclonal antibody and B-lymphocyte stimulator (BLyS/BAFF)-specific inhibitor developed for autoimmune diseases. Belimumab works by binding to soluble BLyS and inhibiting the survival and differentiation of autoreactive B cells, thereby reducing autoimmune-mediated inflammation and fibrosis. The drug received FDA Orphan Drug Designation for systemic sclerosis because the disease is rare, serious, and has limited treatment options, especially for SSc-ILD, which is a major cause of mortality in affected patients. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Scleroderma.

Tibulizumab : Zura Bio Inc

Tibulizumab (ZB-106) is an investigational humanized tetravalent bispecific dual-antagonist antibody being developed for autoimmune and inflammatory diseases, including systemic sclerosis (scleroderma). The drug is engineered as a fusion of the anti-IL-17A antibody ixekizumab and the anti-BAFF antibody tabalumab, allowing simultaneous inhibition of both IL-17A and BAFF pathways that are involved in inflammation, B-cell activation, fibrosis, and immune dysregulation in systemic sclerosis. This dual-pathway mechanism is intended to address the multi-organ inflammatory and fibrotic pathology of scleroderma more effectively than single-pathway inhibition. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Scleroderma.

CABA-201: Cabaletta Bio

CABA-201 is an investigational autologous 4-1BB-containing fully human CD19 chimeric antigen receptor T-cell (CD19-CAR T) therapy being developed for autoimmune diseases, including systemic sclerosis (scleroderma). The therapy is designed to deeply and transiently deplete CD19-positive B cells after a one-time infusion, with the goal of producing an “immune system reset” that may enable durable remission without continuous therapy. The mechanism of action is based on eliminating pathogenic autoreactive B cells that contribute to inflammation, autoantibody production, fibrosis, and organ damage associated with the disease. CABA-201 has received both FDA Orphan Drug Designation and FDA Fast Track Designation for systemic sclerosis. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Scleroderma.

CTX112: CRISPR Therapeutics

CTX112 is an investigational next-generation allogeneic anti-CD19 CAR-T cell therapy engineered using CRISPR/Cas9 gene editing technology. CTX112 is designed to selectively target and deplete CD19-positive B cells that contribute to autoantibody production, inflammation, immune dysregulation, and fibrosis associated with autoimmune disease. The therapy incorporates edits intended to evade immune rejection, enhance CAR-T potency, and reduce T-cell exhaustion. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Scleroderma.

Further product details are provided in the report……..

Scleroderma Drug Therapeutic Assessment

This segment of the report provides insights about the different Scleroderma drugs segregated based on following parameters that define the scope of the report, such as:

Major Scleroderma Players in Scleroderma

There are approx. 45+ key companies which are developing the therapies Scleroderma. The companies which have their Scleroderma drug candidates in the most advanced stage, i.e. Phase III include, GSK, and others.

Scleroderma Clinical Trial Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Scleroderma Drug Route of Administration

Scleroderma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Scleroderma Product Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Scleroderma Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Scleroderma Clinical Trial Activities 

The Scleroderma pipeline report provides insights into different Scleroderma Clinical Trial within phase II, I, preclinical and discovery stage. It also analyses Scleroderma therapeutic drugs key players involved in developing key drugs. 

Scleroderma Pipeline Development Activities

The Scleroderma Clinical Trial Analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Scleroderma drugs.

Scleroderma Pipeline Report Insights

• Scleroderma Pipeline Analysis
• Scleroderma Therapeutic Assessment
• Scleroderma Unmet Needs
• Impact of Scleroderma Drugs

Scleroderma Pipeline Report Assessment

• Scleroderma Pipeline Product Profiles
• Scleroderma Therapeutic Assessment
• Scleroderma Pipeline Assessment
• Scleroderma Inactive drugs assessment
• Scleroderma Market Unmet Needs

Key Questions Answered In the Scleroderma Pipeline Report

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Scleroderma drugs?
• How many Scleroderma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Scleroderma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Scleroderma therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Scleroderma and their status?
• What are the key designations that have been granted to the emerging drugs?

Scleroderma Key Players

• GlaxoSmithKline
• Cabaletta Bio
• Zura Bio Inc
• Shenzhen Huishan Biotechnology Co., Ltd.
• Galderma
• Jiangsu Renocell Biotech Company
• Argenx
• Mediar Therapeutics
• Topadur Pharma AG
• Quell Therapeutics Limited
• Nkarta, Inc.
• Xencor, Inc.
• CRISPR Therapeutics

Scleroderma Key Products

• Belimumab
• CABA-201
• Tibulizumab
• HS_SW01
• Nemolizumab
• RY_SW01
• Efgartigimod PH20 SC
• MTX-474
• TOP-N53
• QEL-005
• NKX019
• XmAb657
• CTX112